Since our transcriptomic analyses showed that IRF2 levels were “rate limiting” for expression of MHC I pathway components and caspase 7 in most patient cancers, our treatment results predict that patients whose cancers have reduced levels of IRF2 transcripts, which we showed can be frequent, will similarly become more resistant to CPI. The gene discussed is IRF2; the disease is cancer.